Novel carbapenem derivatives of quarternary salt type
申请人:——
公开号:US20030022881A1
公开(公告)日:2003-01-30
An objective of the present invention is to provide carbapenem derivatives which have potent antibiotic activity against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase-producing bacteria and are stable against DHP-1. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts thereof:
1
wherein R
1
represents H or methyl; R
2
and R
3
each independently represent H, halogen, lower alkyl or the like; R
4
represents optionally substituted lower alkylthio or the like; and R
5
represents optionally substituted lower alkyl or the like.
[EN] MACROCYCLIC COMPOUNDS FOR TREATING DISEASE<br/>[FR] COMPOSÉS MACROCYCLIQUES POUR LE TRAITEMENT DE MALADIE
申请人:TP THERAPEUTICS INC
公开号:WO2019126121A1
公开(公告)日:2019-06-27
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
[EN] MACROCYCLIC KINASE INHIBITORS AND THEIR USE<br/>[FR] INHIBITEURS MACROCYCLIQUES DE KINASE ET LEUR UTILISATION
申请人:TP THERAPEUTICS INC
公开号:WO2019126122A1
公开(公告)日:2019-06-27
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Magnesium chloride (MgCl2) catalyzed highly regioselective C-3 ring opening of 2,3 epoxy alcohols by N-nucleophile
作者:Amit Kumar、Gautam Panda
DOI:10.1016/j.tetlet.2021.153013
日期:2021.4
herein report Magnesiumchloride (MgCl2) catalyzed first highly C3-selective ring-opening reaction of various 2,3-epoxy alcohols with assorted N-Nucleophiles and sodium azide to furnish 3-amino-1,2 diols and 3-azido-1,2 diols respectively in high yields under mild reactionconditions. This protocol attributes the use of catalytic amount of Magnesiumchloride (MgCl2), simple reactionconditions, practical
The invention relates to novel 1,4-diazepan-2-one compounds, which are TGR5 agonists and useful for the treatment of metabolic disorders, inflammatory diseases, atherosclerosis and dyslipidemias.